Enhanced efficiency of prodrug activation therapy by tumor-selectively replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene

Documenti analoghi

• A Uniquely Stable Replication-Competent Retrovirus Vector Achieves Efficient Gene Delivery in Vitro and in Solid Tumors
  di: LOGG, CHRISTOPHER R., et al.
  Pubblicazione: (2001)
• Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors
  di: Parker, William B., et al.
  Pubblicazione: (2017)
• Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase
  di: Parker, W B, et al.
  Pubblicazione: (2011)
• EXTH-44. DEVELOPMENT OF RETROVIRAL REPLICATING VECTORS ENCODING SEQUENCE-OPTIMIZED NITROREDUCTASE FOR PRODRUG ACTIVATOR GENE THERAPY IN HUMAN GLIOMA MODELS
  di: Collins, Sara, et al.
  Pubblicazione: (2020)
• Therapeutic Efficacy of Replication-Competent Retrovirus Vector–Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model
  di: Hiraoka, Kei, et al.
  Pubblicazione: (2007)